Section Arrow
Quote
NVCR.NASDAQ
- NovoCure Limited
Quotes are at least 15-min delayed:2026/05/14 16:23 EDT
After Hours
Last
 18.06
-- (--)
Bid
18.03
Ask
18.05
High 18.41 
Low 18.05 
Volume 10.52K 
Regular Hours (Closed)
Last
 18.045
-0.055 (-0.30%)
Day High 
18.425 
Prev. Close
18.1 
1-M High
18.92 
Volume 
1.52M 
Bid
18.03
Ask
18.05
Day Low
17.825 
Open
18.13 
1-M Low
10.85 
Market Cap 
2.10B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 17.04 
20-SMA 14.77 
50-SMA 12.93 
52-W High 20.06 
52-W Low 9.82 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.53/-1.07
Enterprise Value
2.33B
Balance Sheet
Book Value Per Share
2.86
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
655.35M
Operating Revenue Per Share
4.35
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
WOKWORK Medical Technology Group LTD.1.3098-1.4502-52.54%-- 
After Hours 1.35 -- --
BSXBoston Scientific Corp53.55+0.49+0.92%22.41PE
After Hours 53.55 0 0.00%
ABTAbbott Laboratories84.9+1.07+1.28%23.78PE
After Hours 85 +0.1 +0.12%
PACBPacific Biosciences of California1.2153-0.0547-4.31%-- 
After Hours 1.2292 -- --
MDTMedtronic plc76.97+0.76+1.00%21.5PE
After Hours 76.97 0 0.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.